statistiche ricercatore

Continente	#
NA - Nord America	1.390
AS - Asia	631
EU - Europa	383
SA - Sud America	80
Continente sconosciuto - Info sul continente non disponibili	33
AF - Africa	9
OC - Oceania	9
Totale	2.535

Nazione	#
US - Stati Uniti d'America	1.340
SG - Singapore	240
CN - Cina	128
IT - Italia	116
VN - Vietnam	85
BR - Brasile	63
DE - Germania	45
GB - Regno Unito	45
AT - Austria	39
HK - Hong Kong	38
BD - Bangladesh	30
CA - Canada	28
ID - Indonesia	23
FR - Francia	22
PL - Polonia	22
JP - Giappone	21
FI - Finlandia	16
IN - India	16
TR - Turchia	15
SE - Svezia	14
RU - Federazione Russa	13
ES - Italia	10
UA - Ucraina	9
AR - Argentina	8
AU - Australia	8
NO - Norvegia	7
PK - Pakistan	7
BE - Belgio	5
CH - Svizzera	5
IQ - Iraq	5
LT - Lituania	5
MX - Messico	5
ZA - Sudafrica	5
NL - Olanda	4
SV - El Salvador	4
HN - Honduras	3
MY - Malesia	3
PA - Panama	3
CO - Colombia	2
EC - Ecuador	2
IE - Irlanda	2
IL - Israele	2
JO - Giordania	2
KE - Kenya	2
KG - Kirghizistan	2
NP - Nepal	2
PH - Filippine	2
PR - Porto Rico	2
PS - Palestinian Territory	2
TT - Trinidad e Tobago	2
TW - Taiwan	2
VE - Venezuela	2
AL - Albania	1
BO - Bolivia	1
CR - Costa Rica	1
EE - Estonia	1
EG - Egitto	1
GR - Grecia	1
JM - Giamaica	1
KZ - Kazakistan	1
NI - Nicaragua	1
NZ - Nuova Zelanda	1
PY - Paraguay	1
QA - Qatar	1
SA - Arabia Saudita	1
SK - Slovacchia (Repubblica Slovacca)	1
SY - Repubblica araba siriana	1
TH - Thailandia	1
TN - Tunisia	1
UY - Uruguay	1
UZ - Uzbekistan	1
Totale	2.502

Nome	#
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists	329
Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia	312
Therapeutic potential of RGS4 blockade in movement disorders	277
Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes	228
NOP receptor ligands and Parkinson’s disease	215
Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson's Disease Models	186
6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata	183
Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats	169
Molecular and imaging prodromal markers of dopamine neuron degeneration in animal models of Parkinson’s disease: pathophysiology and clinical perspectives	165
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease	162
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia	160
Regulator of G-Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor signalling: Implication for L-Dopa-induced dyskinesia	149
Totale	2.535

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	87	0	0	0	2	2	14	8	14	6	7	11	23
2022/2023	171	14	26	11	22	27	24	6	5	19	0	11	6
2023/2024	93	8	4	4	6	8	13	4	11	2	5	4	24
2024/2025	367	5	9	37	5	27	67	2	16	46	65	48	40
2025/2026	1.213	134	34	69	136	202	78	148	80	103	130	76	23
2026/2027	258	33	42	98	85	0	0	0	0	0	0	0	0
Totale													2.535

SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara